New Zealand markets closed
  • NZX 50

    11,258.28
    +120.40 (+1.08%)
     
  • NZD/USD

    0.6350
    -0.0015 (-0.23%)
     
  • ALL ORDS

    7,426.60
    +76.00 (+1.03%)
     
  • OIL

    114.34
    +1.94 (+1.73%)
     
  • GOLD

    1,813.70
    -5.20 (-0.29%)
     

Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference

·1-min read

SAN MATEO, Calif., January 27, 2022--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 B. Riley Securities Oncology Investor Conference being held virtually from January 27-28, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will provide an overview of the company at 2:30 pm ET on Friday, January 28, 2022.

A replay of the presentation will be available following the conference on the Investors section of Sierra’s corporate website in the Events & Webcast tab. The replay will be available for approximately 30 days following the presentation.

About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.

For more information, visit www.SierraOncology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005358/en/

Contacts

Investors
DeDe Sheel
415.732.9828
dsheel@sierraoncology.com

Media
Lauren Musto
615.351.7777
lmusto@sierraoncology.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting